Cel-sci Corporation · AMEX:CVM
Cel-sci — H.C. Wainwright Virtual Fireside Chat Series (June 2020)
10 slides from Cel-sci's conference presentation, Jun 25, 2020
Slide 1: LEAPS COVID 19 Immunotherapy
LEAPS COVID 19 Immunotherapy H.C. Wainwright Virtual Fireside Chat Series June 25, 2020 CEL-SCI Corporation Geert Kersten 8229 Boone Boulevard, Suite 802 NYSE American: CVM Chief Executive Officer Vienna, VA 22182, USA Phone: (703) 506-9460
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally
Slide 3: CEL-SCI Corporation
CEL-SCI Corporation CEL-SCI Corporation (NYSE American: CVM) focuses on the research and development of immunotherapy products for the treatment of cancer, autoimmune and infectious diseases. CEL-SCI’s primary focus is cancer immunotherapy given right after diagnosis, before the ravages of surgery,
Slide 4: Why Develop LEAPS for COVID 19?
Why Develop LEAPS for COVID 19? • Very promising efficacy and safety profiles in animal studies against H1N1 pandemic flu, and five other diseases. We saw both prevention and treatment in H1N1. Using the lessons learned from H1N1 we seek to repeat these promising results against COVID 19 in a transg
Slide 5: Drugs in Development
Drugs in Development • Multikine® - an investigational cancer immunotherapy in a Phase 3 study under development as a potential neoadjuvant (First-Line) treatment of head and neck cancer. This study has been running for over 9 years and is now in the data lock/analysis phase. We believe that adminis
Slide 6: LEAPS (Ligand Epitope Antigen Presentation System) Technology
LEAPS (Ligand Epitope Antigen Presentation System) Technology • CEL‐SCI’s second proprietary technology platform, LEAPS, is a preclinical technology designed to stimulate the human immune system to fight bacterial, viral, and parasitic infections more effectively, as well as autoimmune conditions, a
Slide 7: LEAPS (Ligand Epitope Antigen Presentation System) Technology
LEAPS (Ligand Epitope Antigen Presentation System) Technology The concept behind the LEAPS technology is to directly mimic cell/cell interactions on the T‐cell surface using synthetic peptides. LEAPS immune therapeutic (vaccines) consist of a combination of a small peptide (referred to as a T‐cell b
Slide 8: Prior Results and Current Focus of LEAPS Technology
Prior Results and Current Focus of LEAPS Technology • Animal studies have demonstrated the safety and potential usefulness of specifically designed LEAPS constructs in treating rheumatoid arthritis, experimental allergic myocarditis, collagen induced arthritis (CIA), Proteoglycan induced arthritis (
Slide 9: Why LEAPS against COVID 19?
Why LEAPS against COVID 19? Prior studies (conducted in collaboration with the NIH Laboratory for Emerging Diseases) demonstrated the effectiveness of a LEAPS H1N1 construct in the treatment of Influenza A - H1N1 infected mice. The results against H1N1 were as follows: • Reduced mortality and morbid
Slide 10: Summary
Summary • Second-generation immunotherapy/vaccine technology: create better and more comprehensive immune response suitable for attacking COVID 19. Antibodies and T-cell response. • Proven in animal tests against H1N1 pandemic flu, Herpes simplex and four other diseases. • Able to generate protectiv
CEL-SCI — H.C. Wainwright Virtual Fireside Chat Series (June 2020) on 6ix